Summary
Global
Markets Direct's, 'Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or
Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1
2016', provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein
Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted
pipeline therapeutics.
The
report provides comprehensive information on the Aurora Kinase A
(Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2
or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications,
stage of development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in Aurora Kinase A (Serine/Threonine-Protein Kinase 15
or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted
therapeutics development and features dormant and discontinued projects.
Browse Ongoing
Reports @ http://www.radiantinsights.com/research/aurora-kinase-a-serine-threonine-protein-kinase
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Note*: Certain
sections in the report may be removed or altered based on the availability and
relevance of data.
Scope
-
The report provides a snapshot of the global therapeutic landscape for Aurora
Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or
Aurora 2 or EC 2.7.11.1)
-
The report reviews Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or
Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics
under development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
The report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in Aurora Kinase A
(Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2
or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor
projects
-
The report assesses Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or
Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted therapeutics
based on mechanism of action (MoA), route of administration (RoA) and molecule
type
-
The report summarizes all the dormant and discontinued pipeline projects
-
The report reviews latest news and deals related to Aurora Kinase A
(Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2
or EC 2.7.11.1) targeted therapeutics
No comments:
Post a Comment